Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Serlopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 20/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TACR3 | P29371 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serlopitant SCHEMBL16333766 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL16280735 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL12646287 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL24067973 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL3184271 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL23883105 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL16280736 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL13531608 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL16280639 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL16353223 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-20260008856-A1 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE INC (US) | 2026-01-08 | — | — | US | claimed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | claimed |
| EP-4551249-A2 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Bluefin Biomedicine, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| US-11878074-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2024-01-23 | — | — | US | claimed |
| WO-2024011189-A2 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| US-20230255884-A1 | FINISHED FIBROUS SRUCTURES AND METHODS OF THEIR USE AND PREPARATION | CLEXIO BIOSCIENCES LTD. (IL) | 2023-08-17 | — | — | US | claimed |
| US-9474741-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2016-10-25 | — | — | US | claimed |
| US-20160279100-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-09-29 | — | — | US | claimed |
| US-9381188-B2 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2016-07-05 | — | — | US | claimed |
| US-20160143882-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-05-26 | — | — | US | claimed |
| US-20160038462-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-02-11 | — | — | US | claimed |
| US-9198898-B2 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2015-12-01 | — | — | US | claimed |
| US-20150057255-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2015-02-26 | — | — | US | claimed |
| US-20140378521-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2014-12-25 | — | — | US | claimed |
| US-8906951-B1 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2014-12-09 | — | — | US | claimed |
| US-20100209496-A1 | LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057255-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
| US-20100209496-A1 | LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE | ADH1A, CPT1A, ADH1C | TACR1 2564/4885TACR2 2562/4885CYP3A4 300/4885 |
| US-20160038462-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
| US-20140378521-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | MRGPRX1, MRGPRX2, TACR1 | TACR1 3/4885TACR2 9/4885CYP3A4 1779/4885 |
| US-20160143882-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | TACR1 1/4885TACR2 8/4885CYP3A4 849/4885 |
| US-20260008856-A1 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | IL23R, CCR1, IL1RN | TACR1 200/4885TACR2 1139/4885CYP3A4 3280/4885 |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | P2RX3, P2RX1, P2RX5 | TACR1 141/4885TACR2 323/4885CYP3A4 2958/4885 |
| US-20160279100-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.